Key points
- Binding Heads of Agreement signed with Pro Medicus for up to A$20 million investment
- Investment contingent on FDA clearance of EchoSolv HF
- Pro Medicus to become reseller of EchoSolv in the US
- Transaction expected to accelerate US commercialization efforts
Full summary
Echo IQ Limited (ASX: EIQ) has executed a binding Heads of Agreement (HOA) with Pro Medicus Limited (ASX: PME) to establish a strategic investment and commercial partnership. Under the HOA, Pro Medicus will invest an initial A$10 million in Echo IQ through secured convertible notes, with an option for an additional A$10 million investment contingent on FDA clearance of EchoSolv HF. Pro Medicus will also become a reseller of Echo IQ's EchoSolv product suite in the United States. The proposed partnership aims to leverage Pro Medicus' extensive network and commercial reach to accelerate the adoption of Echo IQ's AI-powered cardiac diagnostic solutions in the US healthcare market.
Outlook
Echo IQ expects the partnership to provide significant validation and access to a leading healthcare technology platform, supporting its strategy to accelerate adoption and commercialization in the US.